Comparison of response to salmeterol/fluticasone combination (SFC) therapy in elderly- versus younger- onset asthma and COPD

Comparison of response to salmeterol/fluticasone combination (SFC) therapy in elderly- versus younger- onset asthma and COPD - Comparison of response to SFC in elderly- versus younger- onset asthma, and COPD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006291

Enrollment

Registered

2011-09-15

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma, COPD

Interventions

Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 24 weeks in younger-onset asthma Salmeterol/fluticasone propionate combination aerosol, 2 puff twice daily, for 12, 2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Asthma: 1, At entry, patients with adult asthma developed within three years. Gender does not matter. 2, Adult patients with mild to moderate persistent asthma. 3, Patient developed in over 65 years registered as elderly-onset asthma. 4, Patient developed in 40 years or less registered as young-onset asthma. COPD: 1, Diagnosed with COPD, and unused inhaled corticosteroid. Gender does not matter. 2, Long term treatment with bronchodilator including long acting beta-agonist. Common criteria: Patient was able to get a written consent from the person.

Exclusion criteria

Exclusion criteria: Asthma: History of smoking. COPD: Current smokers. Common criteria: 1, Diagnosed with non-COPD / non-asthma respiratory disorders and heart diseases. 2, Poor adherence. 3, Use inhaled, oral, and injection steroids within 8 weeks before enrollment. 4, Patients have hypersensitivity to salmeterol or fluticasone propionate, or suspected patient. 5, The patients who are inappropriate considered by physician

Design outcomes

Primary

Measure	Time frame
Asthma control questionnaire (ACQ) Spirometry exhaled nitric oxide exacerbation Asthma Control Test (ACT) COPD Assessment Test (CAT)	—

Secondary

Measure	Time frame
Relevance of changes in the primary Outcomes. The following background factors at start of intervention. Age Gender Height Weight Duration of disease Smoking history Co morbidity Blood test Reversibility of airway. Adverse events, serious adverse events, side effects, number and frequency of serious side effects. The percentage of discontinued patients(%)	—

Countries

Japan

Contacts

Public ContactKazuto Matsunaga

Wakayama Medical university Third Department of Internal Medicine

kazmatsu@wakayama-med.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026